Program
LB-102
Also written as “LB-102 (50 mg tablet)” and “LB-102 (100 mg tablet)”.
Its studies are mostly in Schizophrenia, led by LB Pharmaceuticals.
Furthest: phase 3, since Dec 26, 20256 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LB Pharmaceuticals | 63 open or running | phase 3since Dec 26, 2025 | Nov 26, 2019 | Jun 2027phase 3 · NCT07363577 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 26, 2019First study: phase 1 study in SchizophreniaFirst studyNCT04187560 · 64 enrolled · United States
- Oct 6, 2020Phase 1 study in SchizophreniaNCT04588129 · 16 enrolled · United States
- Dec 12, 2023Phase 2 study in SchizophreniaNCT06179108 · 359 enrolled · United States
- Dec 26, 2025Phase 2 study in Bipolar I DisorderNCT07494305 · 320 planned · United States
- Dec 26, 20252 phase 3 studies in SchizophreniaPhase 3 reachedNCT07369154, NCT07363577
Ahead
- Jun 2027Primary completion: phase 3 study in SchizophreniaNCT07363577
- Feb 2028Primary completion: phase 2 study in Bipolar I DisorderNCT07494305
- Dec 2028Primary completion: phase 3 study in SchizophreniaNCT07369154
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07494305Bipolar I Disorder · United States | 2 | Recruiting | Feb 2028 | 320 |
| NCT07369154Schizophrenia · United States | 3 | Recruiting | Dec 2028 | 900 |
| NCT07363577Schizophrenia · United States | 3 | Recruiting | Jun 2027 | 456 |
| NCT06179108Schizophrenia · United States | 2 | Completed | Dec 4, 2024 | 359 |
| NCT04588129Schizophrenia · United States | 1 | Completed | Sep 17, 2021 | 16 |
| NCT04187560Schizophrenia · United States | 1 | Completed | Jul 1, 2020 | 64 |
How it is read
Names in the registry
- “LB-102”, 5 entries
- “LB-102 (50 mg tablet)”, 1 entry
- “LB-102 (100 mg tablet)”, 1 entry
Conditions, from the studies’ own filings
- Schizophrenia, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.